Late-stage oral therapy designed to reduce bacterial exacerbations, hospital admissions and the healthcare burden of COPD Melbourne, Australia; New York, USA; and London, UK – XX June 2026 – Respien Pty Ltd (“Respien”), an Australian biopharmaceutical company developing novel respiratory therapies, has appointed Sage Healthcare Ltd and The Sage Group Inc. (collectively “Sage”) to lead a global partnering process for HI-164, Respien’s lead Phase 3-ready respiratory asset. HI-1

Acquisition adds complementary asset to the Pelthos commercial portfolio Xeglyze is a novel, FDA-approved prescription medication indicated for the topical treatment of head lice infestation in patients 6 months of age and older DURHAM, N.C., Jan. 05, 2026 (GLOBE NEWSWIRE) — Pelthos Therapeutics Inc. (NYSE American: PTHS), a biopharmaceutical company committed to commercializing innovative therapeutic products for unmet patient needs (“Pelthos”), today announced it has acquir

EXXUA is now available through Aytu RxConnect® pharmacies to ensure optimal access and availability EXXUA has demonstrated significant improvement in depression symptoms in clinical trials involving more than 5,000 patients and, notably, has no warnings or adverse events related to sexual dysfunction and no clinically significant weight gain compared to placebo DENVER, CO / ACCESS Newswire / December 15, 2025 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a

Manassas, VA - Serpin Pharma is pleased to announce a strategic partnership with Dogwood Therapeutics to develop and commercialize SP16,...